{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["18(4)"],"submitter":["Darnaud L"],"pubmed_abstract":["<h4>Background</h4>Isavuconazole is a new antifungal prodrug for the treatment of invasive aspergillosis and mucormycosis. As no clear pharmacokinetic-pharmacodynamic relationship has been established for patients, therapeutic drug monitoring is not currently required. However, as isavuconazole is a new drug, clinicians are sometimes sceptical about the exposure achieved in their patients and seek pharmacokinetic exploration. A minimal response consists of determining that the patient's pharmacokinetic profile agrees with profiles reported by Desai et al. using concentrations from the SECURE study.<h4>Methods</h4>Based on one concentration and Desai et al.'s population-pharmacokinetic model, it is possible to estimate a patient's most likely pharmacokinetic profile. If a patient's pharmaco"],"journal":["Drugs in R&D"],"pagination":["317-321"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6277320"],"repository":["biostudies-literature"],"pubmed_title":["Isavuconazole Kinetic Exploration for Clinical Practice."],"pmcid":["PMC6277320"],"pubmed_authors":["Venisse N","Martins P","Pontier S","Concordet D","Darnaud L","Godet C","Lamoureux F","Debard A","Gandia P"],"additional_accession":[]},"is_claimable":false,"name":"Isavuconazole Kinetic Exploration for Clinical Practice.","description":"<h4>Background</h4>Isavuconazole is a new antifungal prodrug for the treatment of invasive aspergillosis and mucormycosis. As no clear pharmacokinetic-pharmacodynamic relationship has been established for patients, therapeutic drug monitoring is not currently required. However, as isavuconazole is a new drug, clinicians are sometimes sceptical about the exposure achieved in their patients and seek pharmacokinetic exploration. A minimal response consists of determining that the patient's pharmacokinetic profile agrees with profiles reported by Desai et al. using concentrations from the SECURE study.<h4>Methods</h4>Based on one concentration and Desai et al.'s population-pharmacokinetic model, it is possible to estimate a patient's most likely pharmacokinetic profile. If a patient's pharmaco","dates":{"release":"2018-01-01T00:00:00Z","publication":"2018 Dec","modification":"2025-05-29T21:45:14.796Z","creation":"2025-05-29T21:45:14.796Z"},"accession":"S-EPMC6277320","cross_references":{"pubmed":["30306415"],"doi":["10.1007/s40268-018-0251-y"]}}